[A26-16] Colchicine (prophylaxis of ischaemic cardiovascular events after myocardial infarction) – Benefit assessment according to §35a Social Code Book V
Last updated 01.06.2026
Project no.:
A26-16
Commission:
Commission awarded on 27.02.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Heart and circulation
In addition to standard therapies for prophylaxis of ischaemic cardiovascular events in adult patients with atherosclerotic coronary artery disease and a recent myocardial infarction
Hint of a non-quantifiable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A26-16